Cover concerns.
作者信息
Kovesi Tom
出版信息
Can Fam Physician. 2010 Apr;56(4):329-30.
Abstract
摘要
相似文献
1
Cover concerns.涵盖相关问题。
Can Fam Physician. 2010 Apr;56(4):329-30.
2
Safety of β2-agonists: a 50-year debate closed?β2激动剂的安全性：一场持续50年的争论结束了吗？
Eur Respir J. 2014 Jan;43(1):6-9. doi: 10.1183/09031936.00193813.
3
Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.长效β2受体激动剂在哮喘管理中的安全性：加拿大初级保健呼吸联盟的观点
Can Fam Physician. 2010 Feb;56(2):119-20, 123-4.
4
Concerns with beta2-agonists in pediatric asthma - a clinical perspective.小儿哮喘中β2-激动剂的关注——临床视角。
Paediatr Respir Rev. 2017 Jan;21:80-85. doi: 10.1016/j.prrv.2016.05.006. Epub 2016 Jun 16.
5
Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol.长效β2受体激动剂在常规哮喘治疗中的安全性评估：ASTRO-LAB方案。
NPJ Prim Care Respir Med. 2015 Jun 18;25:15040. doi: 10.1038/npjpcrm.2015.40.
6
Sudden cardiac death caused by the administration of a β₂-agonist for asthma attack.因使用β₂受体激动剂治疗哮喘发作而导致的心源性猝死。
Int J Cardiol. 2011 Dec 15;153(3):e56-8. doi: 10.1016/j.ijcard.2011.02.041. Epub 2011 Mar 10.
7
Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma.一种新型静脉用β2肾上腺素能激动剂（贝多拉德林，MN - 221）治疗哮喘急性加重患者的疗效。
Respir Med. 2015 Oct;109(10):1268-73. doi: 10.1016/j.rmed.2015.08.003. Epub 2015 Aug 14.
8
LABAs and asthma: from the SMART study to the SMART approach.长效β2受体激动剂与哮喘：从SMART研究到SMART方法
Indian J Chest Dis Allied Sci. 2010 Oct-Dec;52(4):191-3.
9
Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada.加拿大胸科学会哮喘委员会关于加拿大哮喘患者使用长效β2受体激动剂的评论。
Can Respir J. 2010 Mar-Apr;17(2):57-60. doi: 10.1155/2010/378289.
10
Use of magnesium in moderating tachycardia in acute severe asthma in pregnancy.镁在孕期急性重症哮喘中控制心动过速的应用。
Br J Anaesth. 2013 Jun;110(6):1059. doi: 10.1093/bja/aet146.
本文引用的文献
1
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.升级治疗用于接受吸入皮质类固醇治疗但哮喘控制不佳的儿童。
N Engl J Med. 2010 Mar 18;362(11):975-85. doi: 10.1056/NEJMoa1001278. Epub 2010 Mar 2.
2
Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults.加拿大胸科协会哮喘管理连续性--2010 年共识总结，适用于 6 岁及以上儿童和成人。
Can Respir J. 2010 Jan-Feb;17(1):15-24. doi: 10.1155/2010/827281.
3
Must family physicians use spirometry in managing asthma patients?: NO.家庭医生在管理哮喘患者时必须使用肺活量测定法吗？：不必。
Can Fam Physician. 2010 Feb;56(2):127, 129, 131, 133; discussion e50, e52.
4
Must family physicians use spirometry in managing asthma patients?: YES.家庭医生在管理哮喘患者时必须使用肺活量测定法吗？：必须使用。
Can Fam Physician. 2010 Feb;56(2):126, 128, 130,132; discussion e49, e51.
5
Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.长效β2受体激动剂在哮喘管理中的安全性：加拿大初级保健呼吸联盟的观点
Can Fam Physician. 2010 Feb;56(2):119-20, 123-4.
6
Achieving control of asthma in preschoolers.实现学龄前儿童哮喘的控制。
CMAJ. 2010 Mar 9;182(4):E172-83. doi: 10.1503/cmaj.071638. Epub 2009 Nov 23.
7
Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group.沙美特罗添加治疗与加倍倍氯米松剂量治疗儿童哮喘的比较。荷兰哮喘研究小组。
Am J Respir Crit Care Med. 1998 Jul;158(1):213-9. doi: 10.1164/ajrccm.158.1.9706048.
Zotero 插件